Toggle Main Menu Toggle Search

Open Access padlockePrints

Adherence to treatment in men with hypogonadotrophic hypogonadism

Lookup NU author(s): Dr Richard Quinton


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


© 2016 John Wiley & Sons Ltd Objective: Men with congenital hypogonadotrophic hypogonadism (CHH) typically require lifelong hormonal therapy, and discontinuing treatment can have negative health consequences. Little is known about adherence to treatment or the psychosocial impact of CHH. Design: A sequential, multiple methods approach was used. A quantitative online survey assessed adherence to treatment, depressive symptoms and illness perceptions. Subsequently, qualitative focus groups explored patient-reported factors for adherence. Patients: Adult men with CHH on at least 1 year of treatment were recruited internationally. Measurements: Adherence (Morisky medication adherence scale), depressive symptoms (Zung self-rating depression scale) and patient perception of CHH (revised illness perception questionnaire) were assessed in an online survey, and comparisons were made to reference groups. Patient focus group discussions were conducted and thematic analysis was employed to identify patient-reported factors for adherence. Results: In total, 101 men on long-term treatment were included (mean age 37 ± 11 years). Forty three percent (43/101) exhibited low medication adherence and a significantly elevated prevalence of mild, moderate or severe depressive symptoms (27%, 17%, 20%, respectively, all P < 0·001 vs reference population). Patients reported negative illness perceptions and significant psychosocial consequences. Focus group discussions (n = 3, 26 total patients) identified patient-, health professional- and healthcare system-related barriers as targets for improving adherence. Conclusions: Congenital hypogonadotrophic hypogonadism men are challenged to adhere to long-term treatment. Poor adherence may contribute to adverse effects on bone, sexual and psychological health. The psychosocial morbidity of CHH is significant and appears to be underappreciated by healthcare providers.

Publication metadata

Author(s): Dwyer AA, Tiemensma J, Quinton R, Pitteloud N, Morin D

Publication type: Article

Publication status: Published

Journal: Clinical Endocrinology

Year: 2017

Volume: 86

Issue: 3

Pages: 377-383

Print publication date: 01/03/2017

Online publication date: 20/09/2016

Acceptance date: 15/09/2016

ISSN (print): 0300-0664

ISSN (electronic): 1365-2265

Publisher: Blackwell Publishing Ltd


DOI: 10.1111/cen.13236


Altmetrics provided by Altmetric